Christoph Uleer
About
Christoph Uleer is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research.
According to data from OpenAlex, Christoph Uleer has authored 47 papers receiving a total of 917 indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Oncology, 23 papers in Pulmonary and Respiratory Medicine and 23 papers in Cancer Research. Recurrent topics in Christoph Uleer's work include Advanced Breast Cancer Therapies (21 papers), Breast Cancer Treatment Studies (19 papers) and Cancer Treatment and Pharmacology (17 papers). Christoph Uleer is often cited by papers focused on Advanced Breast Cancer Therapies (21 papers), Breast Cancer Treatment Studies (19 papers) and Cancer Treatment and Pharmacology (17 papers). Christoph Uleer collaborates with scholars based in Germany, United States and Switzerland. Christoph Uleer's co-authors include Michael Clemens, Gϋnter von Minckwitz, Robert C. Stein, Andreas du Bois, Marcus Schmidt, Felix E. de Jongh, Valentina Nekljudova, Sibylle Loibl, Manfred Kaufmann and Wolfgang Bauer and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.
In The Last Decade
Christoph Uleer
42 papers receiving 893 citations
Hit Papers
Peers
Christoph Uleer
Martin Olivo United States
Ruigang Cai China
K. Aogi Japan
Guorong Yang China
Quchang Ouyang China
C. Hudis United States
Ronald Linnartz United States
Iben Kümler Denmark
Olga Martínez‐Sáez Spain
Peter F. Lenehan United States
Citations per year, relative to Christoph Uleer Christoph Uleer (= 1×)
peers
Martin Olivo
Countries citing papers authored by Christoph Uleer
Since
Specialization
Citations
This map shows the geographic impact of Christoph Uleer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christoph Uleer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christoph Uleer more than expected).
Fields of papers citing papers by Christoph Uleer
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Christoph Uleer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christoph Uleer. The network helps show where Christoph Uleer may publish in the future.
Co-authorship network of co-authors of Christoph Uleer
This figure shows the co-authorship network connecting the top 25 collaborators of Christoph Uleer. A scholar is included among the top collaborators of Christoph Uleer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christoph Uleer. Christoph Uleer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Bauer, Marcus, Jochen Wilke, Volker Hanf, et al.. (2024). Prognostic and predictive impact of NOTCH1 in early breast cancer. Breast Cancer Research and Treatment. 209(1). 27–38.
2.
Lüftner, Diana, Florian Schuetz, Andreas Schneeweiß, et al.. (2024). Efficacy and safety of everolimus plus exemestane in patients with hormone receptor‐positive, HER ‐2‐negative advanced breast cancer: Results from the open‐label, multicentre, non‐interventional BRAWO study. International Journal of Cancer. 155(1). 128–138.
3.
Bethmann, Daniel, Tilmann Lantzsch, Christoph Uleer, et al.. (2022). Prognostic Value of Tumour-Infiltrating Lymphocytes in an Unselected Cohort of Breast Cancer Patients. Diagnostics. 12(10). 2527–2527.
4.
Uleer, Christoph, Volker Hanf, Marcus Bauer, et al.. (2022). PIK3CA-mutations in breast cancer. Breast Cancer Research and Treatment. 196(3). 483–493.
5.
Kolberg-Liedtke, Cornelia, Friedrich Feuerhake, Matthias Christgen, et al.. (2022). Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial. Breast Cancer Research. 24(1). 58–58.
6.
Staege, Martin S., Volker Hanf, Tilmann Lantzsch, et al.. (2021). Identifying High-Risk Triple-Negative Breast Cancer Patients by Molecular Subtyping. Breast Care. 16(6). 637–647.
7.
Gluz, Oleg, Ulrike Nitz, Matthias Christgen, et al.. (2021). Prognostic impact of recurrence score, endocrine response and clinical-pathological factors in high-risk luminal breast cancer: Results from the WSG-ADAPT HR+/HER2- chemotherapy trial.. Journal of Clinical Oncology. 39(15_suppl). 504–504.
8.
Hauke, Jan, Corinna Ernst, Peter A. Fasching, et al.. (2020). 176P Germline mutation status and therapy response in patients with homologous recombination deficient, HER2-negative early breast cancer: Results of the GeparOLA study (NCT02789332). Annals of Oncology. 31. S313–S313.
9.
Nitz, Ulrike, Oleg Gluz, Michael Clemens, et al.. (2019). West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer. Journal of Clinical Oncology. 37(10). 799–808.
10.
Bauer, Marcus, Eva Johanna Kantelhardt, Thorsten Stiewe, et al.. (2019). Specific allelic variants of SNPs in the MDM2 and MDMX genes are associated with earlier tumor onset and progression in Caucasian breast cancer patients. Oncotarget. 10(20). 1975–1992.
11.
Gluz, Oleg, Ulrike Nitz, C Liedtke, et al.. (2018). Prognostic impact of anthracyclines and immune/proliferation markers in TNBC according to pCR after de-escalated neoadjuvant chemotherapy with 12 weeks of nab-paclitaxel/carboplatin or gemcitabine: Survival results of WSG-ADAPT-TN phase II trial. Annals of Oncology. 29. viii703–viii703.
12.
Gluz, Oleg, Ulrike Nitz, Matthias Christgen, et al.. (2017). Prognostic impact of recurrence score (RS), grade/Ki67 central pathological review, and acycline (A)-free vs. A-containing chemotherapy (CT) on distant and locoregional disease-free survival (DDFS/LRFS) in high clinical risk HER2- early breast cancer (EBC): WSG PlanB trial results. Annals of Oncology. 28. v606–v606.
13.
Bernhardt, Stephan, Michaela Bayerlová, Martina Vetter, et al.. (2017). Proteomic profiling of breast cancer metabolism identifies SHMT2 and ASCT2 as prognostic factors. Breast Cancer Research. 19(1). 112–112.
14.
Gluz, Oleg, Cornelia Liedtke, Aleix Prat, et al.. (2017). Association of molecular subtype, proliferation, and immune genes with efficacy of carboplatin versus gemcitabine addition to taxane-based, anthracycline-free neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC): Results of the randomized WSG ADAPT-TN trial.. Journal of Clinical Oncology. 35(15_suppl). 573–573.
15.
Ginsberg, Norman, et al.. (2016). The role of cervical cultures to guide perioperative antibiotics in cervical cerclage – a retrospective analysis of 65 consecutive cases. The Journal of Maternal-Fetal & Neonatal Medicine. 29(22). 3629–3633.
16.
Uleer, Christoph, et al.. (2013). Relevance of Health Economics in the Early Detection of Breast Cancer in Germany - the View of the Professional Association of Practicing Gynecologic Oncologists e.V. (BNGO). Breast Care. 8(1). 35–39.
17.
Nitz, Ulrike, Oleg Gluz, I. Zuna, et al.. (2013). Final results from the prospective phase III WSG-ARA trial: impact of adjuvant darbepoetin alfa on event-free survival in early breast cancer. Annals of Oncology. 25(1). 75–80.
18.
Uleer, Christoph, et al.. (2012). Long-Term Partial Remission with Capecitabine/ Trastuzumab in a Patient with Metastatic Breast Cancer Following Progression on Trastuzumab Alone. Breast Care. 7(1). 45–47.
19.
Gluz, Oleg, Matthias Christgen, C Liedtke, et al.. (2012). Abstract P2-10-08: Prospective comparison of Recurrence Score and different definitions of luminal subtypes by central pathology assessment of single markers in early breast cancer: results from the phase III WSG-planB Trial. Cancer Research. 72(24_Supplement). P2–10.
20.
Uleer, Christoph, et al.. (2011). Multifocal invasive ductal breast cancer with osteoclast-like giant cells: a case report. Journal of Medical Case Reports. 5(1). 85–85.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Martin Olivo Breakdown of academic impact, for papers by Ruigang Cai Breakdown of academic impact, for papers by K. Aogi Breakdown of academic impact, for papers by Guorong Yang Breakdown of academic impact, for papers by Quchang Ouyang Breakdown of academic impact, for papers by C. Hudis Breakdown of academic impact, for papers by Ronald Linnartz Breakdown of academic impact, for papers by Iben Kümler Breakdown of academic impact, for papers by Olga Martínez‐Sáez Breakdown of academic impact, for papers by Peter F. Lenehan